<DOC>
	<DOCNO>NCT00806910</DOCNO>
	<brief_summary>Heart Failure grow challenge public health concern United States . Heart failure commonly manifest syndrome salt water retention . Arginine vasopressin peptide hormone intimately involved salt water homeostasis . AVP release circulation response low blood volume hypernatraemia . Despite fluid overload , vasopressin level often inappropriately elevated patient heart failure LV dysfunction . Data suggest vasopressin may also contribute deleterious circulatory response patient heart failure play role development progression disease process . In study , Udelson et al . show vasopressin receptor antagonism Conivaptan result significant diuresis stable hemodynamics advance heart failure patient . Currently Intravenous diuretic vasodilator standard care treat patient acute decompensated heart failure . We study renal diuretic effect add therapy intravenous Conivaptan patient receive intravenous Nesiritide intravenous diuretic .</brief_summary>
	<brief_title>Diuretic Renal Effects Vaprisol When Administered Along With Furosemide Nesiritide Continuous Infusion</brief_title>
	<detailed_description>Heart failure effect 5 6 million Americans increase prevalence . There 550 , 000 new case heart failure every year 3 million admission acute decompensated heart failure every year . The total cost heat failure health system upwards 35 billion dollar per year . Despite advance medical care , hospital readmission rate 20 % one month 50 % six month . This prevailing situation mandate exploration novel therapeutic target treat complex disease . Vasopressin level often elevate patient heart failure LV dysfunction paradoxical inappropriate . It hypothesize high level circulate vasopressin may play important role pathophysiology heart failure syndrome also contribute disease progression . Studies show Conivaptan , Vasopressin antagonist result favorable change hemodynamics urine output without affect blood pressure heart rate . No consensus reach Conivaptan use sole agent Acute Decompensated Heart Failure ( ADHF ) patient IV loop diuretic and/or vasodilator Nesiritide use prime treatment vascular congestion . This prevailing situation bring question whether , Conivaptan use adjunct IV Furosemide and/or Nesiritide present ADHF.We intend investigate question cohort heart failure patient hyponatremia . This study enroll 60 patient ( meet inclusion criterion none exclusion criterion ) , admit Albert Einstein Medical Center diagnosis Acute Decompensated Heart Failure ( New York Heart Association class 3 4 ) . The study population divide 2 group ; treatment group placebo group describe . Each group comprise 30 patient . The treatment group treat Nesiritide infusion , intravenous Furosemide ( either continuous infusion bolus injection- total dose Furosemide receive end study calculate ) IV Vaprisol . The placebo group give Nesiritide infusion intravenous Furosemide ( either continuous infusion bolus injection ) placebo . Treatment continue group 24-36 hour .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<criteria>Patients age 18 able consent LVEF â‰¤40 % ( measure within last 6 month enter study ) Patients Acute Decompensated Heart Failure ( ADHF ) ( NYHA class 3 &amp; 4 ) Patients estimate GFR &gt; 40ml/min calculate CockcroftGault MDRD formula Serum Sodium level &lt; 135 meq/L Ability understand willing sign inform consent Willingness followup clinic outpatient Patients Acute Coronary Syndrome ( ACS : Unstable angina , NSTEMI STEMI ) Patients pressor ( include Vasopressin analog ) hemodynamic stability Supine systolic blood pressure &lt; 100 mm Hg Hypersensitivity Conivaptan Concomitant use medication affect hepatic drug metabolism ( e.g . Ketoconazole , Itraconazole , Ritonavir , Indinavir , Clarithromycin etc . ) Significant liver dysfunction ( ALT &amp; AST twice upper limit normal ) Uncontrolled bradyarrhythmias tachyarrhythmias Pacemaker defibrillator implantation cardiac surgery &lt; 60 day Severe obstructive pulmonary disease Significant uncorrected valvular congenital heart disease Obstructive cardiomyopathy Significant renal impairment ( define serum creatinine &gt; 2.5 mg/dL creatinine clearance &lt; 40 ml/min ) . Radiocontrast infusion within &lt; 7 day Pregnant lactate female subject Untreated severe hyperthyroidism , hypothyroidism adrenal insufficiency Expected requirement emergent treatment hypernatremia course study Known urinary outflow obstruction , unless subject , catheterized study Serum albumin &lt; 1.5 gm/dl document time time seven day prior study drug administration Any concurrent illness , opinion investigator , may interfere treatment evaluation safety . White blood cell count ( WBC ) count &lt; 3000 /mL document time seven day prior study drug administration anticipate drop WBC count &lt; 3000/mL period study due chemotherapy . Participation another clinical trial investigational drug ( include placebo ) device within 30 day screen entry present study Subject moderate ascites physical examination secondary hepatic dysfunction ( ascites primarily relate cardiac dysfunction allow long subject cardiac cirrhosis ) . Subject moderate severe hepatic impairment evidence ChildPugh B C criterion . Subject history hepatic encephalopathy , hematemesis melena . Subjects alter mental status due severe hyponatremia . Patient belong vulnerable population institutionalize person , prisoner person decisional incapacity dementia . Patients medication know cause drug interaction Nicardipine , lovastatin , Ritonovir , Doxorubicin Etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>conivaptan</keyword>
	<keyword>Diuresis</keyword>
</DOC>